<DOC>
	<DOCNO>NCT00375739</DOCNO>
	<brief_summary>The purpose study determine whether topical application PEP005 safe treatment actinic keratoses .</brief_summary>
	<brief_title>Study Determine Safety PEP005 0.025 % 0.05 % Topical Gel Patients With Actinic Keratoses</brief_title>
	<detailed_description>Actinic keratoses ( AK ) common skin condition characterize rough , scaly patch sores top layer skin leave untreated progress skin cancer . Current treatment cause scar hypopigmentation , inconvenient , require long treatment duration . Non-invasive alternative therapy treatment AK lesion thus research .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Inclusion 1 . Male patient least 18 year age . 2 . Postmenopausal female patient i.e. , menses least 12 consecutive month , without uterus . 3 . 4 8 clinically typical , visible discrete AK lesion within contiguous 25 cm2 treatment area arm , shoulder , chest , back scalp . 4 . Screening laboratory value within reference range define central laboratory `` range '' test result clinically acceptable Investigator . 5 . Ability follow study instruction likely complete study requirement . 6 . Written inform consent obtain . 7 . Written Authorization Use Release Health Research Study Information obtain . 8 . Agreement patient allow photograph select AK treatment area take used part study data package . Exclusion 1 . Females child bear potential ( female consider childbearing potential unless postmenopausal , i.e. , menses least 12 consecutive month , without uterus ) . 2 . Location select AK treatment area : 1. anywhere face 2. within 5 cm incompletely heal wound 3. breast area woman 4. dorsum hand 3 . AK lesion atypical clinical appearance e.g . hypertrophic , hyperkeratotic , recalcitrant disease ( cryosurgery 2 previous occasion ) , cutaneous horn within select AK treatment area . 4 . Presence suspect basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) within select AK treatment area within 10 cm select AK treatment area . 5 . Presence know suspect metastatic disease . 6 . History evidence skin condition AK would interfere evaluation study drug ( e.g . eczema , unstable psoriasis , xeroderma pigmentosa ) . 7 . Known sensitivity ingredient study drug . 8 . A cosmetic therapeutic procedure ( e.g . use liquid nitrogen , surgical excision , curettage , dermabrasion , medium great depth chemical peel , laser resurface ) : within 2 cm select AK treatment area 4 week prior screen visit 9 . Treatment 5fluorouracil , imiquimod , diclofenac , masoprocol photodynamic therapy : within 2 cm select AK treatment area 24 month prior screen visit anywhere 4 week prior screen visit 10 . Treatment immunomodulators ( e.g . vinblastine , podophyllin , colhamin , camptothecin ) , cytotoxic drug ( e.g . cyclophosphamide , azathiopine , chlorambucil , nitrogen mustard , methotrexate ) , interferon/ interferon inducer : within 4 week prior screen visit 11 . Use acidcontaining therapeutic product ( e.g . salicylic acid fruit acid , alpha beta hydroxy acid glycolic acid ) , topical retinoids light chemical peel : within 2 cm select AK treatment area 4 week prior screen visit 12 . Treatment psoralen plus UVA ( PUVA ) use UVB therapy : anywhere 6 month prior screen visit 13 . Use systemic retinoids ( e.g . isotretinoin , acitretin , bexarotene ) : within 6 month prior screen visit 14 . Anticipated excessive prolonged exposure ultraviolet light ( e.g . sunlight , tan bed ) . 15 . Use topical salve , artificial tanner topical steroid : On select AK treatment area 4 week prior screen visit 16 . Anticipated need hospitalization ( inpatient ) surgery ( except specify exclusion criterion 8 ) study . 17 . Concurrent disease suppress immune system ( e.g . HIV , hepatitis ) . 18 . Uncontrolled systemic disease ( e.g . uncontrolled hypertension [ systolic blood pressure 180 mmHg great and/or diastolic blood pressure 110 mmHg great ] , poorly control diabetes [ fast blood sugar 350 mg/dl great ] ) . 19 . Use systemic medication suppress immune system ( e.g . cyclosporine , prednisone , methotrexate , alefacept , infliximab ) : within 4 week prior screen visit 20 . Current evidence chronic alcohol drug abuse . 21 . Current enrollment investigational drug device study participation study within 30 day entry study entry another investigational drug device study enrol study . 22 . A condition situation Investigator 's opinion may put patient significant risk , may confound study result , may interfere significantly patient 's participation study [ e.g . patient required hospitalization 2 month prior screen acute chronic condition ] . 23 . Selected AK treatment area within 5 cm AK lesion previously treat PEP005 , patient participate earlier PEP005 topical gel trial . Patients enrol Treatment Phase 1 reenrolled Treatment Phase 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>Topical</keyword>
	<keyword>Solar Keratosis</keyword>
	<keyword>Sun Spots</keyword>
	<keyword>Dermatology</keyword>
</DOC>